Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Sun Pharma

Tracked across 76 events · 3512 articles · First seen Jan 07, 2025 · Last active Sep 23, 2026

Sentiment
8
Attention
8
Events
76
Relationships
52
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 0
Business
Impact: Sun Pharma Ltd. announced the schedule for its second quarter 2026 financial results release and subsequent conference call and webcast. This event is a routine financial disclosure for the company.
Jun 18, 2026 · 6 articles
4 70
Business
Impact: Sun Pharma acquired Emalex Biosciences, strengthening its late-stage neuroscience pipeline with Ecopipam and advancing its Pivot to Growth strategy. This acquisition is expected to support near- and long-term growth for Sun Pharma.
Jun 10, 2026 · 8 articles
2 10
Business
Impact: Sun Pharma Ltd. is participating in the Goldman Sachs Global Healthcare Conference, providing an opportunity to present its strategies and outlook to investors and the financial community.
Jun 01, 2026 · 6 articles
4 70
Business
Impact: Sun Pharma launched AHZANTIVE, a biosimilar to Eylea, in Europe, expanding its biosimilars portfolio and presence in ophthalmology, aligning with its Pivot to Growth strategy.
Jun 04, 2026 · 7 articles
3 60
Business
Impact: Teva is the developer of TEV-408 and announced the Phase 2b advancement, which supports its pipeline and growth strategy, positively impacting its stock.
Jul 07, 2026 · 7 articles
3 20
Business
Impact: Teva secures exclusive global rights to commercialize the biosimilar, advancing its Pivot to Growth strategy and expanding its biosimilars pipeline.
Jul 09, 2026 · 14 articles
3 20
Regulatory
Impact: Sun Pharma received regulatory approval to market generic semaglutide in South Africa, its second market after India, enhancing its product portfolio and access to the diabetes treatment market.
Jul 15, 2026 · 8 articles
2 10
Business
Impact: Sun Pharma reported a 27% rise in Q1 net profit and 10.5% revenue growth, driven by India and innovative medicines, while US generics declined. The company is progressing on its Organon acquisition, expected to close in early 2027.
Jul 31, 2026 · 7 articles
2 -30
Regulatory
Impact: Sun Pharma initiated the precautionary withdrawal of multiple eye drop products in India due to a contamination scare, instructing distributors to stop billing and return stocks. This action may lead to short-term revenue loss and reputational risk, but the company's emphasis on patient safety could help maintain trust.
Aug 01, 2026 · 7 articles
4 -20
Regulatory
Impact: Teva is the defendant seeking to exclude references to its Israeli origin to ensure a fair trial. The outcome could affect its legal exposure and reputation.
Aug 06, 2026 · 6 articles
4 70
Regulatory
Impact: Teva is the developer and sponsor of ecopipam; the FDA acceptance advances its neuroscience pipeline and growth strategy, with shares rising in pre-market trading.
Aug 19, 2026 · 7 articles
4 80
Tech
Impact: Teva is the developer of TEV '408 and announced the positive Phase 2a results, which could significantly enhance its pipeline value and growth prospects.
Sep 02, 2026 · 6 articles
4 70
Business
Moody s Ratings and S&P Global Ratings assigned investment-grade credit ratings to Sun Pharma Industries, India's largest pharmaceutical company, in connection with its proposed USD 11.75 billion acquisition of US-based Organon & Co. S&P assigned…
Impact: Sun Pharma is the subject of the rating actions and the acquirer in the USD 11.75 billion Organon deal. The investment-grade ratings and expected revenue growth to about USD 14 billion by FY28 strengthen its credit profile and market position.
Sep 08, 2026 · 6 articles
1 0
Business
Sun Pharma Ltd. announced on September 23, 2026 that its Q3 2026 Aide Memoire is available on the Investors page of its website. The document was compiled from public information previously provided by Teva, including…
Impact: Teva is the sole subject of the event, publishing its Q3 2026 Aide Memoire to help investors prepare for results due November 3, 2026. The disclosure is neutral for the company, carrying no new financial information or guidance.
Sep 23, 2026 · 6 articles
1 0
Business
Sun Pharma announced on September 23, 2026 that it will release its third quarter 2026 financial results on Tuesday, November 3, 2026 at 7:00 a.m. ET. The company will follow the release with a conference…
Impact: Teva is the sole subject of the announcement, scheduling its Q3 2026 earnings release and conference call for November 3, 2026. The notice itself is neutral for the company's valuation, with investor focus deferred to the actual results.
Sep 23, 2026 · 7 articles
4 20
Regulatory
Impact: Sun Pharma>>> is responsible for the commercialization of AVT16 under a partnership with Alvogen>>>, which could expand its product portfolio if approved.
Jun 08, 2026 · 11 articles
4 50
Regulatory
Impact: Teva is the commercialization partner for AVT80; the regulatory progress supports its biosimilar portfolio and potential revenue.
Aug 31, 2026 · 9 articles
6 45
Domestic
On August 31, 2026, President Donald Trump announced voluntary drug pricing agreements with nine pharmaceutical companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These companies agreed…
Impact: Sun Pharma extended MFN pricing to United States — Medicaid and future launches, gaining a two-year tariff reprieve. The deal supports its planned $11.75 billion acquisition of Organon & Co., though shares dipped about 1%.
Aug 18, 2026 · 37 articles
4 10
Business
Impact: Sun Pharma>>> is partnered with Alvogen>>> for the commercialization of AVT05 and AVT06. The resubmission of BLAs by Alvogen>>> is a positive development for Sun Pharma>>> as it moves closer to potentially commercializing these biosimilars.
Jun 04, 2026 · 10 articles
2 50
Domestic
Impact: Sun Pharma participated, reflecting potential investment in pharmaceutical manufacturing in India — Gujarat.
Sep 02, 2026 · 9 articles
4 -20
International
Impact: Sun Pharma was among the firms that saw declines in the S&P BSE Sensex.
Jan 08, 2026 · 7 articles
4 20
Tech
Impact: Sun Pharma is one of the 23 leading pharmaceutical companies included in the Indian Pharmaceutical Alliance, which is a partner in the Indian AI Research Organization (IAIRO) project.
Dec 30, 2025 · 7 articles
2 0
Business
Impact: Sun Pharma, a generic drug manufacturer, settled with UroGen Pharma Ltd. to receive a non-exclusive license to sell a generic version of Jelmyto starting September 15, 2030. This will introduce future competition for UroGen Pharma Ltd.'s product.
Jun 14, 2026 · 6 articles
4 20
Business
Impact: Sun Pharma was among the winning stocks, contributing to the overall market gains.
Jul 03, 2026 · 7 articles
4 -20
Regulatory
Impact: Sun Pharma also offers generic semaglutide; the expanded Wegovy indication could affect its competitive position.
Jul 17, 2026 · 13 articles
4 -10
Business
Impact: Sun Pharma was among the laggards in the Sensex.
Jul 17, 2026 · 20 articles
4 0
Regulatory
Impact: Acquired Ranbaxy from Daiichi; not directly involved in the current proceedings.
Aug 31, 2026 · 11 articles
4 10
Business
Impact: Sun Pharma was among the winners, as pharma stocks saw some buying.
Aug 10, 2026 · 43 articles
3 -10
Business
Impact: Sun Pharma's Leqselvi is a competitor JAK inhibitor; potential competitive pressure from bempikibart.
Jul 13, 2026 · 6 articles
6 20
International
Impact: Gained as a top gainer.
Jul 06, 2026 · 105 articles
+ 46 more events View on Dashboard
70 Sun Pharma secured bridge loanSun Pharma Organon...
60 Sun Pharma donated active pharmaceutical ingredients United StatesTrump announces nine new...
60 Sun Pharma announced earnings release dateTeva Releases Q3 2026 Aide Memoire
60 Sun Pharma announced earnings release dateTeva Sets Q3 2026 Earnings...
40 Sun Pharma contributed antibioticsTrump announces nine new...
Astec LifeSciences competitor ↔ Sun Pharma Sun Pharma competes directly with Astec LifeSciences and its related entities in
Abbott Laboratories competitor ↔ Sun Pharma Sun Pharmaceutical Industries acts as a major competitor to Abbott Laboratories
Astec LifeSciences competitor ↔ Sun Pharma Astec LifeSciences, alongside its associated life sciences brands, operates as a
Abbott Laboratories competitor ↔ Sun Pharma Abbott Laboratories competes directly with Sun Pharma in the global pharmaceutic
Organon & Co. ↔ Sun Pharma
Organon & Co. ↔ Sun Pharma
Trent Limited ↔ Sun Pharma
Trent Limited ↔ Sun Pharma
UltraTech Cement ↔ Sun Pharma
UltraTech Cement ↔ Sun Pharma
Bharti Airtel ↔ Sun Pharma
Bharti Airtel ↔ Sun Pharma
ITC Limited ↔ Sun Pharma
ITC Limited ↔ Sun Pharma
Larsen & Toubro ↔ Sun Pharma
Larsen & Toubro ↔ Sun Pharma
HCLTech ↔ Sun Pharma
Hang Seng Index ↔ Sun Pharma
HCLTech ↔ Sun Pharma
Hang Seng Index ↔ Sun Pharma
+ 22 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track Sun Pharma live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.